...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Modern Pathology >The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors
【24h】

The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors

机译：新的分子标记DDIT3，STT3A，ARG2和FAM129A无法用于诊断甲状腺滤泡性肿瘤

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Preoperative characterization of thyroid follicular lesions is challenging. Fine-needle aspiration specimens cannot differentiate follicular carcinomas from benign follicular neoplasias. Recently, promising markers have been detected using modern molecular techniques. We conducted a retrospective study to confirm the usefulness of immunohistochemical staining for the protein markers, DDIT3, STT3A (ITM1), ARG2 and FAM129A (C1orf24) in separating benign and malignant thyroid follicular lesions. Formalin-fixed, paraffin-embedded thyroid tissue from 30 in-house cases (15 follicular carcinomas and 15 follicular adenomas), as well as 8 follicular carcinomas and 21 follicular adenomas on tissue microarray slides were stained immunohistochemically for DDIT3, STT3A, ARG2 and FAM129A expression. Control tissue consisted of thyroid parenchyma adjacent to the tumors and 11 separate cases of normal thyroid parenchyma. All in-house cases of follicular adenomas, follicular carcinomas and adjacent normal thyroid tissue showed positive immunostaining with anti-DDIT3 and anti-STT3A. Anti-ARG2 and anti-FAM129A polyclonal antibodies showed positive staining in 20 and 60% of in-house follicular adenomas, and 40 and 87% of in-house follicular carcinomas, respectively. Monoclonal anti-FAM129A demonstrated positive staining in 13 and 33% of in-house follicular adenomas and follicular carcinomas, respectively. Polyclonal anti-DDIT3, -STT3A and -FAM129A antibodies showed positive staining in all tissue microarray slides of follicular carcinoma and in 76, 85 and 81% of the follicular adenomas, respectively. Monoclonal anti-STT3A stained 81% of the follicular adenoma cores. Anti-ARG2 stained positive in 13% of follicular carcinomas and 10% of follicular adenomas on the tissue microarray slides. In conclusion, DDIT3, STT3A, ARG2 and FAM129A immunohistochemistry does not appear to be useful in the diagnosis of thyroid follicular neoplasias, as they do not reliably distinguish follicular thyroid carcinoma from follicular thyroid adenoma.
机译：甲状腺滤泡性病变的术前表征具有挑战性。细针抽吸标本不能区分滤泡性癌和良性滤泡性瘤。最近，使用现代分子技术已经检测到有前途的标记。我们进行了一项回顾性研究，以确认免疫组织化学染色对蛋白质标志物DDIT3，STT3A（ITM1），ARG2和FAM129A（C1orf24）在分离良性和恶性甲状腺滤泡性病变中的作用。用免疫组织化学方法对DDIT3，STT3A，ARG2和FAM129A进行免疫组织化学染色，对30个内部病例（15个滤泡癌和15个滤泡腺瘤）以及8个滤泡癌和21个滤泡腺瘤进行福尔马林固定，石蜡包埋的甲状腺组织的免疫组织化学染色表达。对照组织由靠近肿瘤的甲状腺实质和11例正常甲状腺实质组成。所有内部滤泡性腺瘤，滤泡性癌和邻近的正常甲状腺组织病例均显示抗DDIT3和抗STT3A阳性免疫染色。抗ARG2和抗FAM129A多克隆抗体分别在20％和60％的室内滤泡性腺瘤以及40％和87％的室内滤泡性癌中显示阳性染色。单克隆抗FAM129A分别在13％和33％的内部滤泡性腺瘤和滤泡癌中显示阳性染色。多克隆抗DDIT3，-STT3A和-FAM129A抗体在滤泡癌的所有组织微芯片玻片中以及在76％，85％和81％的滤泡性腺瘤中均显示阳性染色。单克隆抗STT3A染色了81％的滤泡性腺瘤核心。组织芯片阵列载玻片上，在13％的滤泡癌和10％的滤泡腺瘤中，抗ARG2染色呈阳性。总之，DDIT3，STT3A，ARG2和FAM129A免疫组织化学似乎不能用于甲状腺滤泡性瘤的诊断，因为它们不能可靠地将滤泡性甲状腺癌与滤泡性甲状腺腺瘤区分开。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号